Biotech News

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Replimune Group (REPL)Replimune Group2026-06-25 13:46 ESTEarnings

April 10, 2026 Target Action Date for RP1 in Advanced Melanoma WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the

Open original release

Related news

REPLReplimune Group2026-06-25 13:46 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPLReplimune Group2026-06-25 13:46 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPLReplimune Group2026-06-25 13:46 EST

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

REPLReplimune Group2026-06-25 13:46 EST

Replimune Provides Update Following Type A Meeting with FDA

REPLReplimune Group2026-06-25 13:46 EST

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

REPLReplimune Group2026-06-25 13:46 EST

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

REPLReplimune Group2026-06-25 13:46 EST

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

REPLReplimune Group2026-06-25 13:46 EST

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

REPLReplimune Group2026-06-25 13:46 EST

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

REPLReplimune Group2026-06-25 13:46 EST

Replimune to Present at Two Upcoming Investor Conferences

View all latest news

Replimune Group

Replimune Group is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

REPLReplimune Group2026-06-26 10:41 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPLReplimune Group2026-06-26 10:41 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPLReplimune Group2026-06-26 10:41 EST

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

REPLReplimune Group2026-06-26 10:41 EST

Replimune Provides Update Following Type A Meeting with FDA

REPLReplimune Group2026-06-26 10:41 EST

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States